Leuprolide Acetate

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

42 Suppliers, 28 USDMF, 15 CEP/COS, 5 JDMF, 4 EU WC, 9 KDMF, 60 NDC API, 18 Listed Suppliers

DEVELOPMENTS

17 Drug(s) in Development

17 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Imports

DOSSIERs // Finished Dosage Forms

173 Dossiers, 33 FDA Orange Book, 81 Europe, 11 Canada, 11 Australia, 7 South Africa, 30 Listed Dossiers

DRUG PRODUCT COMPOSITION

POWDER;INTRAMUSCULAR - 11.25MG, POWDER;INTRAMUSCULAR - 15MG, POWDER;INTRAMUSCULAR - 3.75MG,7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER;INTRAMUSCULAR - 30MG, POWDER;INTRAMUSCULAR - 45MG, POWDER;INTRAMUSCULAR - 7.5MG, POWDER;INTRAMUSCULAR - 7.5MG,7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE, TABLET;INTRAMUSCULAR, ORAL - 11.25MG/VIAL,N/A;N/A,5MG, INJECTABLE, TABLET;INTRAMUSCULAR, ORAL - 3.75MG/VIAL,N/A;N/A,5MG

RELATED EXCIPIENT COMPANIES

Suppliers, 3 Actylis, 1 Finar, 1 Nanjing Well Pharmaceutical

EXCIPIENTS BY APPLICATIONS

3 Parenteral, 2 Topical, 1 Solubilizers

GLOBAL SALES INFORMATION

40 US Medicaid Prescriptions, 42 Finished Drug Prices

MARKET PLACE

8 APIs, 7 DOSSIERS // FDF

PATENTS

8 US Patents, 1 US Exclusivities, 10 Health Canada Patents

ANALYTICAL SOLUTION(s)

2 EDQM Standards, 1 USP Standards, 1 JP Standards, 2 Other Ref. Standards

DIGITAL CONTENT

1 Data Compilation & Company Tracker #PharmaFlow, 33 News

Annual Sales of Leuprolide Acetate reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Leuprolide Acetate

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

42 Suppliers

28 USDMF

15 CEP/COS

5 JDMF

4 EU WC

9 KDMF

60 NDC API

18 Listed Suppliers

DEVELOPMENTS

17 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Imports

DOSSIERs // Finished Dosage Forms

173 Dossiers

33 FDA Orange Book

81 Europe

11 Canada

11 Australia

7 South Africa

30 Listed Dossiers

DRUG PRODUCT COMPOSITION

POWDER;INTRAMUSCULAR - 11.25MG

POWDER;INTRAMUSCULAR - 15MG

POWDER;INTRAMUSCULAR - 3.75MG,7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

POWDER;INTRAMUSCULAR - 30MG

POWDER;INTRAMUSCULAR - 45MG

POWDER;INTRAMUSCULAR - 7.5MG

POWDER;INTRAMUSCULAR - 7.5MG,7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE, TABLET;INTRAMUSCULAR, ORAL - 11.25MG/VIAL,N/A;N/A,5MG

INJECTABLE, TABLET;INTRAMUSCULAR, ORAL - 3.75MG/VIAL,N/A;N/A,5MG

RELATED EXCIPIENT COMPANIES

Suppliers

3 Actylis

1 Finar

1 Nanjing Well Pharmaceutical

EXCIPIENTS BY APPLICATIONS

3 Parenteral

2 Topical

1 Solubilizers

GLOBAL SALES INFORMATION

40 US Medicaid Prescriptions

42 Finished Drug Prices

MARKET PLACE

8 APIs

7 DOSSIERS // FDF

PATENTS

8 US Patents

1 US Exclusivities

10 Health Canada Patents

ANALYTICAL SOLUTION(s)

2 EDQM Standards

1 USP Standards

1 JP Standards

2 Other Ref. Standards

DIGITAL CONTENT

1 Data Compilation & Company Tracker #PharmaFlow

33 News

Leuprolide Acetate

Abbvie

Leuprolide Acetate

Lupron

Oncology

USD

892

829

892

829

63

8%

Astellas

Leuprolide Acetate

Eligard

POWDER;INTRAMUSCULAR - 3.75MG,7.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POWDER;INTRAMUSCULAR - 7.5MG,7.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons